Ipsen S.A./€IPN
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Ipsen S.A.
Ipsen S.A. is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. The company focuses on the development and commercialization of innovative medicines in targeted therapeutic areas such as oncology, neuroscience, and rare diseases. Ipsen's key products include Somatuline, a treatment for neuroendocrine tumors and acromegaly, and Dysport, used for movement disorders and aesthetic indications. Founded in 1929 by Henri Beaufour, Ipsen has since expanded its presence worldwide, with a strategic emphasis on specialty care and the development of differentiated products. The company leverages its scientific expertise and research capabilities to sustain its competitive position in the biopharmaceutical industry.
Ticker
€IPN
Sector
Primary listing
PAR
Industry
Pharmaceuticals
Headquarters
Employees
5,358
ISIN
FR0010259150
Website
Ipsen S.A. Metrics
BasicAdvanced
€8.7B
25.28
€4.15
0.60
€1.40
1.33%
Price and volume
Market cap
€8.7B
Beta
0.6
52-week high
€123.92
52-week low
€86.78
Average daily volume
72K
Dividend rate
€1.40
Financial strength
Current ratio
1.343
Quick ratio
0.953
Long term debt to equity
9.393
Total debt to equity
12.411
Dividend payout ratio (TTM)
28.79%
Interest coverage (TTM)
36.35%
Profitability
EBITDA (TTM)
1,191.5
Gross margin (TTM)
82.69%
Net profit margin (TTM)
9.68%
Operating margin (TTM)
23.49%
Effective tax rate (TTM)
17.33%
Revenue per employee (TTM)
€670,000
Management effectiveness
Return on assets (TTM)
7.75%
Return on equity (TTM)
8.93%
Valuation
Price to earnings (TTM)
25.277
Price to revenue (TTM)
2.428
Price to book
2.07
Price to tangible book (TTM)
8.99
Price to free cash flow (TTM)
65.268
Free cash flow yield (TTM)
1.53%
Free cash flow per share (TTM)
160.72%
Dividend yield (TTM)
1.33%
Forward dividend yield
1.33%
Growth
Revenue change (TTM)
8.11%
Earnings per share change (TTM)
-46.30%
3-year revenue growth (CAGR)
9.15%
10-year revenue growth (CAGR)
10.37%
3-year earnings per share growth (CAGR)
-18.82%
10-year earnings per share growth (CAGR)
8.33%
3-year dividend per share growth (CAGR)
5.27%
10-year dividend per share growth (CAGR)
5.12%
Bulls say / Bears say
Ipsen has initiated a share buy-back program to repurchase up to 600,000 shares, approximately 0.72% of its share capital, over six months, signaling confidence in its financial health and potentially increasing shareholder value. (tradingview.com)
The company reported solid results in 2024, driven by strong performance across all therapeutic areas, and provided positive guidance for 2025, indicating robust operational execution and growth prospects. (wfla.com)
Ipsen has approximately €2 billion in firepower for dealmaking, with plans to pursue acquisitions that could exceed the size of its previous $952 million purchase of Albireo Pharma, suggesting a strategic focus on growth through M&A. (bloomberg.com)
Ipsen's top-selling cancer medicine, Somatuline, is facing increased competition from generic versions, which could lead to a decline in sales and impact overall revenue. (bloomberg.com)
The company's debt-to-equity ratio rose to about 0.8 from 0.35 due to recent acquisitions and financing activities, potentially indicating increased financial leverage and associated risks. (reuters.com)
Ipsen's stock has dropped 4.5% this year, compared to a 17% increase in a Bloomberg index tracking European drugmakers, suggesting underperformance relative to peers. (bloomberg.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ipsen S.A. stock?
Ipsen S.A. (IPN) has a market cap of €8.7B as of July 16, 2025.
What is the P/E ratio for Ipsen S.A. stock?
The price to earnings (P/E) ratio for Ipsen S.A. (IPN) stock is 25.28 as of July 16, 2025.
Does Ipsen S.A. stock pay dividends?
Yes, the Ipsen S.A. (IPN) stock pays dividends to shareholders. As of July 16, 2025, the dividend rate is €1.4 and the yield is 1.33%. Ipsen S.A. has a payout ratio of 28.79% on a trailing twelve-month basis.
When is the next Ipsen S.A. dividend payment date?
The next Ipsen S.A. (IPN) dividend payment date is unconfirmed.
What is the beta indicator for Ipsen S.A.?
Ipsen S.A. (IPN) has a beta rating of 0.6. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.